Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
share Share

Corbus Pharmaceuticals Holdings, Inc, an immunology company announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.  


"Anne is a dynamic leader with a proven track record of advancing R&D programs and creating corporate value through successful business development transactions," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Her corporate development expertise and oncology R&D experience will be invaluable to Corbus as we advance and expand our pipeline. We are excited to welcome Anne to our board."  


Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as the Chief Business Officer of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development and program management over 15 years across large pharmaceutical organizations. Specifically, Dr. Altmeyer served as Vice President in Global Business Development at Baxalta and Vice President in Oncology Business Development and Companion Diagnostics at Novartis. Dr. Altmeyer began her industry career in program management roles at Merck & Company. She received her PhD from the University Louis Pasteur, Strasbourg, France, and did her postdoctoral fellowships at New York University and Cornell University Medical College in New York City. She also has an MBA from Rutgers University and a Masters in Public Health from the Robert Wood Johnson Medical School, in New Jersey.


Dr. Altmeyer said, "I am honored to join the Corbus Board and I look forward to working with the Corbus Team and the Board toward advancing the mission of developing new immune-oncology therapeutics for cancer patients." Yuval Cohen, Chief Executive Officer of Corbus added, "Having Anne join us provides Corbus with a valuable resource. Her decades of experience in oncology drug development and business strategy will help guide Corbus through the execution of our expanding pipeline and the partnerships we will need to establish to do so."


Source: Corbus Pharmaceuticals 

«« U.S. Preventive Services Task Force Recommends Screening for Anxiety


NHS Rolls Out New Electric Vehicles to Cut Emissions and Improve Patient Care »»

Published on : Mon, 26 Sep 2022



Related Articles

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction announced it... Read more

R-Zero, a global leader in biosafety technology announced that its Board of Directors has appointed Jennifer Nuckles as Chief... Read more

Mallinckrodt  plc, a global specialty pharmaceutical company announced that it has appointed  Susan Silbermann  to its Board... Read more

Corbus Pharmaceuticals,immunology ,Anne Altmeyer, ,board of directors Corbus Pharmaceuticals Holdings, Inc, an immunology company announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.

No comment


Please login to leave a comment...